A diverse range of parasites can induce disease in humans, differing in terms of their size, life cycle and the clinical response induced in the host (Supplementary information S1 (Table) ). They include unicellular protozoan and multicellular metazoan organisms, such as worms, that complete part or all of their life cycle in an immunocompetent host. One of the most important functions of any pathogen is to secure its transmission to a new host. For most air-borne pathogens (such as respiratory viruses and bacteria), the short time frame for transmission that is dictated by acute infection is adequate to ensure their spread, and there is no need to subvert the rapid onset of sterilizing immunity. By contrast, the low transmissibility of blood and tissue parasites that depend on an invertebrate host for cyclical transmission, such as African trypanosomes, Plasmodium spp., Leishmania spp. and Trypanosoma cruzi, as well as filarial and schistosome worms, requires that the development of sterilizing immunity is delayed and/or ineffective in order to prolong the time available to the parasite for transmission to the vector or intermediate host. It is therefore not surprising that most parasites have developed strategies to avoid elimination by the immune system (Supplementary information S2 (Figure) ).
It is important to note that the failure of the immune system to eliminate transmissible parasites is not necessarily associated with clinical disease; which, in many cases, is prevented by a surprisingly swift and effective induction of immunity. For example, although children in sub-Saharan Africa suffer the greatest mortality from Plasmodium falciparum malaria, most experience only mild disease that is controlled, at least in part, by the immune response. In addition, their risk of severe malaria-associated disease is reduced after only one or two clinical episodes of malaria 1 , and a higher transmission intensity in a given area correlates with a younger age at which immunity develops. Importantly, many of these 'immune' individuals remain infectious (that is, they still harbour live parasites) 2 . The prevalence of parasitaemic individuals begins to decline only among older children indicating that anti-parasitic immunity takes longer to develop than anti-disease immunity.
Age-prevalence studies have also been carried out to understand the development of immunity to schisto somiasis. Children in endemic areas are heavily infected with schistosomes, whereas adults in the same areas often show low or no detectable infection 3 . The ability to clear schistosome infections by effective drug treatment has allowed reinfection studies. These studies have confirmed that despite equal exposure to water infested with infective-stage larvae, children are rapidly reinfected, often to pre-treatment levels, whereas adults are mostly resistant to reinfection 4 . In addition, in areas of high transmission, immunity to infection seems to develop at a younger age 5 , suggesting that immunity is acquired as a consequence of the sum of a certain number of exposures. Taken together, these studies are consistent with the hypothesis that immunity to malaria parasites and to schistosomes can develop but does so slowly. In addition, there is an age-dependent component of naturally acquired immunity to both P. falciparum and Schistosoma spp. infections, as suggested by studies of migrant people [6] [7] [8] . Following migration from a non-endemic to an endemic region, the prevalence of these infections was similar in children and adults in the first year after migration, but within 20 months for P. falciparum and 3 years for Schistosoma mansoni, adults showed low or no detectable infection, whereas children remained heavily infected, similar to life-long residents of the endemic region. Thus, there seems to be an adult-intrinsic immunity to these parasites that can develop rapidly, but that is lacking in children.
Interestingly, most individuals infected with Leishmania spp. develop strong and long-lasting protection against subsequent disease following a single, primary exposure. However, sterile immunity is rarely achieved and both asymptomatic and clinically cured individuals can harbour transmissible parasites and can serve as the main infection reservoirs for emerging and re-emerging disease. Thus, immunity in this setting is not necessarily slow to develop, but is inefficient.
Parasites have evolved numerous mechanisms of immune evasion that underlie the slow or incomplete development of immunity. These mechanisms are as varied as the organisms themselves. Protozoan pathogens have faster propagation rates than slowly maturing multicellular helminths and thus can use clonal antigenic variation to avoid immune-mediated clearance. By altering their surface antigenic coat, new variants of African trypanosomes emerge that are not recognized by the antibodies that are induced by preceding variants; the infection is characterized by waves of blood parasitaemia that makes the host a long-term reservoir of infection for the tsetse fly vector 9 . The delayed development of immunity to the blood-stage infection of malaria (which is responsible for both disease and the generation of transmissible sexual stages of P. falciparum) is also due, at least in part, to antigenic variation. To avoid clearance from the blood during the passage of infected erythrocytes through the spleen, P. falciparum exports parasite-derived proteins -of which the best characterized is P. falciparum erythrocyte membrane protein 1 (PfemP1) 10 -to the surface of erythrocytes. These proteins bind to specific receptors on venular endothelial cells and allow the parasite to remain in the periphery. Host antibodies that recognize these proteins prevent adherence of infected erythrocytes to venular endothelium, and a system of clonal antigenic variation (PfemP1 is encoded by over 50 'var' genes per genome) is required to maintain peripheral sequestration and transmission potential of the parasite. The gradual acquisition of a repertoire of antibodies to all the parasite variants circulating in the population, as occurs in older children, is associated with the reduced prevalence of parasitaemic individuals 11 . As worms do not replicate in their human host, rapid antigenic variation cannot be a mechanism for avoiding sterilizing immunity. However, they have exploited their larger genome size to evolve several alternative, more complex, immune evasion mechanisms. The large size of helminth parasites suggests that the number of antigens that need to be recognized for an effective immune response is wide and varied, and accordingly the immune response takes longer to develop. Furthermore, for helminths such as filaria, schistosomes and hookworms, the rapid migration of the larvae out of the skin means that they may go unnoticed by the host's adept immune sensing mechanisms in the skin. Vaccination with irradiated (attenuated) larvae of each of these parasites, which reside in the skin for a much longer time and induce more inflammation, leads to the development of strong immunity 12 .
For some helminths, it has been shown that they can mask themselves from an effective immune response by acquiring antigens from their host 13 . more importantly, there have been numerous studies showing that some helminths can induce regulatory immune responses to dampen parasite-specific immunity and allow their long-term survival and successful transmission. In turn, the induction of immune regulation could benefit the host by limiting immunopathology.
Several helminth-derived molecules have been characterized that interact with various cells of the immune system and suppress responses or promote functional regulatory T (T reg ) cells 14 . T reg cells and suppressive cytokines are also thought to be key to the persistence of Leishmania spp. parasites in both non-healing and self-limiting forms of leishmaniasis. Interleukin-10 (Il-10) produced by multiple cell types, including T reg cells and innate immune cells, has been shown to contribute to the chronicity of cutaneous and visceral leishmaniasis in mice and humans 15 . Il-10 suppresses T helper 1 (T H 1)-type immune responses to limit the frequency and function of effector cells in target organs such as the skin and spleen and is probably induced as part of a homeostatic process to control tissue damage due to excessive infection-induced inflammation. moreover, Il-10-producing T reg cells allow Leishmania major to persist in mice following clinical cure, establishing the host as a long-term reservoir of the parasite for its sand fly vector 16 .
As recently discussed from an evolutionary perspective 17, 18 , to minimize the impact that a pathogen has on health, there is the option to eliminate the infectious agent, conferring 'resistance' , but there is also the option to minimize the pathology inflicted, conferring 'tolerance' . Parasite immune evasion strategies, including antigenic variation, acquisition of host antigens and induction of regulatory networks (Supplementary information S2 (Figure) ), have evolved primarily to prevent or delay host resistance. Parasite-specific vaccines aimed at conferring resistance will need to somehow overcome these immune evasion mechanisms and outperform the immune response to natural infection. It may be more feasible to develop a vaccine that mimics the host's (and parasite's) successful drive for tolerance, whereby parasites can persist without causing much damage to the host.
